Vantage logo

Sanofi goes back to Scribe

The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.

Vantage logo

UCB leads the stale scale

Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.